Brief: Protalix Biotherapeutics Reports Fiscal Year 2025 Financial And Business Results
18/03/2026 11:20
March 18 (Reuters) - Protalix Biotherapeutics Inc PBDA.F: PROTALIX BIOTHERAPEUTICS REPORTS FISCAL YEAR 2025 FINANCIAL AND BUSINESS RESULTS PROTALIX BIOTHERAPEUTICS INC: EXPECTS TOTAL REVENUES IN 2026 TO RANGE FROM APPROXIMATELY $78.0 MILLION TO $83.0 MILLION Source text: ID:nPn4hHBlza Further company coverage: PBDA.F ((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Protalix Biotherapeutics
See all newsIsrael's Protalix Q1 revenue surges on Chiesi milestone
Brief: Protalix BioTherapeutics Q1 EPS USD 0.23
Brief: Protalix Biotherapeutics Reports Fiscal Year 2025 Financial And Business Results
Brief: EU Approves Four‑week Dosing Option For Chiesi and Protalix’s Elfabrio
Brief: Protalix Biotherapeutics And Secarna Pharmaceuticals Enter Into Collaboration And Option Agreement